Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. [electronic resource]
Producer: 20200727Description: 1149-e807 p. digitalISSN:- 1549-490X
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Docetaxel -- administration & dosage
- Humans
- Kallikreins -- blood
- Male
- Middle Aged
- Neoplasm Metastasis
- Prednisone -- administration & dosage
- Prostate-Specific Antigen -- blood
- Prostatic Neoplasms, Castration-Resistant -- blood
- Quinazolines -- administration & dosage
- Survival Rate
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- blood
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.